Description
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Location: CPMC (San Francisco)
Please contact ClinicalResearch@sutterhealth.org about study AZ TOPAZ-1
View study details on ClinicalTrials.govPrincipal Investigator
Recruitment Status
Active, Recruiting
Start Date
September 10, 2019